

Melanocortin Receptor 4 (MC4R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/MC36B12989A2EN.html>

Date: July 2022

Pages: 66

Price: US\$ 3,500.00 (Single User License)

ID: MC36B12989A2EN

Abstracts

Melanocortin Receptor 4 (MC4R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Melanocortin Receptor 4 (MC4R) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report Melanocortin Receptor 4 - Drugs In Development, 2022, outlays comprehensive information on the Melanocortin Receptor 4 (MC4R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Melanocortin Receptor 4 (MC4R) - Melanocortin 4 receptor (MC4R) is a G protein-coupled receptor involved in the hypothalamic leptin-melanocortin signaling pathway. MC4R is encoded by the MC4R gene. Activation of the MC4R plays a key role in the maintenance of energy homeostasis and is associated with suppression of food intake. The molecules developed by companies in Pre-Registration, Phase III, Phase I and Preclinical stages are 1, 3, 3 and 2 respectively.

Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System, Genetic Disorders, Genito Urinary System And Sex Hormones,

Musculoskeletal Disorders, Oncology and Women's Health which include indications Obesity, Anorexia Nervosa, Cachexia, Cancer Anorexia-Cachexia Syndrome, Female Hypoactive Sexual Desire Disorder, Female Sexual Dysfunction, IgA Nephropathy (Berger's Disease), Metabolic Syndrome, Smith-Magenis Syndrome (Chromosome 17p11.2 Deletion Syndrome) and Type 2 Diabetes.

Furthermore, this report also reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Melanocortin Receptor 4 (MC4R)

The report reviews Melanocortin Receptor 4 (MC4R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Melanocortin Receptor 4 (MC4R)+ targeted therapeutics and enlists all their major and minor projects

The report assesses Melanocortin Receptor 4 (MC4R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Melanocortin Receptor 4 (MC4R) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Melanocortin Receptor 4 (MC4R)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Melanocortin Receptor 4 (MC4R) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope

Contents

Introduction

Global Markets Direct Report Coverage

Melanocortin Receptor 4 (MC4R) - Overview

Melanocortin Receptor 4 (MC4R) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Melanocortin Receptor 4 (MC4R) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Melanocortin Receptor 4 (MC4R) - Companies Involved in Therapeutics Development

Endevica Bio

LG Chem Ltd

Mallinckrodt Plc

Palatin Technologies Inc

Pfizer Inc

Rhythm Pharmaceuticals Inc

Melanocortin Receptor 4 (MC4R) - Drug Profiles

bremelanotide acetate - Drug Profile

Product Description

Mechanism Of Action

History of Events

corticotropin - Drug Profile

Product Description

Mechanism Of Action

History of Events

LB-54640 - Drug Profile

Product Description

Mechanism Of Action

History of Events

PF-07258669 - Drug Profile

Product Description

Mechanism Of Action

History of Events

PL-8905 - Drug Profile

Product Description

Mechanism Of Action

History of Events

PL-9610 - Drug Profile

Product Description

Mechanism Of Action

setmelanotide - Drug Profile

Product Description

Mechanism Of Action

History of Events

setmelanotide hydrochloride ER - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Agonize MC4-R for Obesity - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Antagonize Melanocortin-4 Receptor for Cachexia - Drug Profile

Product Description

Mechanism Of Action

TCMCB-07 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Melanocortin Receptor 4 (MC4R) - Dormant Products

Melanocortin Receptor 4 (MC4R) - Discontinued Products

Melanocortin Receptor 4 (MC4R) - Product Development Milestones

Featured News & Press Releases

Jul 26, 2022: Palatin announces preliminary fourth quarter Vyleesi net product revenue increased 225% over prior quarter

Jul 22, 2022: Rhythm Pharmaceuticals receives positive CHMP opinion for IMCIVREE(setmelanotide) for the treatment of obesity and control of hunger in patients with Bardet-Biedl Syndrome

Jul 20, 2022: Rhythm pharmaceuticals announces early access authorization for setmelanotide for use in patients with Bardet-Biedl syndrome in France

Jul 20, 2022: Rhythm Pharmaceuticals announces early access authorization for setmelanotide for use in patients with Bardet-Biedl Syndrome in France

Jul 18, 2022: NICE recommends Rhythm's IMCIVREE (setmelanotide) for treating obesity and controlling hunger caused by POMC or LEPR Deficiency

Jul 13, 2022: Endevida Bio doses first patient in phase 1 clinical trial of TCMCB07 for the treatment of cachexia

Jul 12, 2022: Rhythm Pharmaceuticals announces positive interim results from phase 2 clinical trial evaluating setmelanotide in hypothalamic obesity

Jun 28, 2022: Endevida reports the U.S. FDA accepted its Investigational New Drug (IND) Application for TCMCB07, a Melanocortin-4 Antagonist Peptide

Jun 22, 2022: Rhythm Pharmaceuticals launches IMCIVREE (setmelanotide) in Germany for the treatment of obesity and control of hunger associated with POMC or LEPR deficiency

Jun 22, 2022: Rhythm Pharmaceuticals announces that European Commission authorized variation for IMCIVREE (setmelanotide) to allow for dosing in patients with POMC or LEPR deficiency with renal impairment

Jun 16, 2022: LG Chem's new drug for obesity receives additional orphan drug designation by the US FDA

Jun 16, 2022: Rhythm Pharmaceuticals announces FDA approval of IMCIVREE (setmelanotide) for use in patients with Bardet-Biedl Syndrome

Jun 13, 2022: Rhythm Pharmaceuticals presents new data from long-term extension trial evaluating Setmelanotide in Bardet-Biedl Syndrome or POMC or LEPR deficiency obesity at ENDO 2022

May 17, 2022: New retrospective data on African Americans with advanced symptomatic sarcoidosis treated with Acthar Gel (repository corticotropin injection) presented at the American Thoracic Society Annual International Conference

May 02, 2022: Rhythm Pharmaceuticals presents new data from phase 3 trial evaluating setmelanotide in patients with Bardet-Biedl Syndrome (BBS) at the Pediatric Endocrine Society (PES) 2022 Virtual Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Endevica Bio, 2022
Pipeline by LG Chem Ltd, 2022
Pipeline by Mallinckrodt Plc, 2022
Pipeline by Palatin Technologies Inc, 2022
Pipeline by Pfizer Inc, 2022
Pipeline by Rhythm Pharmaceuticals Inc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Melanocortin Receptor 4 (MC4R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/MC36B12989A2EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MC36B12989A2EN.html>